Most people who ask how to taper off a GLP-1 are asking two questions at once. Does stepping the dose down soften the landing compared with stopping, and does the landing eventually end somewhere other than the starting weight? One of those now has a randomized answer. The other has none at all, and the gap between them is the most useful thing on this page. What a clean stop produces is measured in the withdrawal article.
What the word taper is doing in this class
In most of medicine a taper is a schedule with an end: a decreasing sequence that terminates in no drug. Applied to obesity pharmacotherapy the word has quietly come to mean something else — a step down to a lower maintenance dose that continues indefinitely, or a stretch of the interval between injections. Those are different interventions with different evidence behind them, and only one of them has been randomized.
The trial that lowered the dose instead of stopping
SURMOUNT-MAINTAIN is a 112-week phase 3b trial run at 20 United States sites. Adults with obesity, or overweight with a weight-related comorbidity, took open-label tirzepatide at their maximum tolerated dose — 10 mg or 15 mg — for 60 weeks. 441 entered that phase and 378 were then randomized 3:3:2 to continue at the maximum tolerated dose, to reduce to 5 mg, or to switch to placebo for a further 52 weeks.[1]
At week 112, the modeled change in body weight from baseline was −21.9% (95% CI, −23.5 to −20.3) on the maximum tolerated dose, −16.6% (95% CI, −18.0 to −15.1) on 5 mg, and −9.9% (95% CI, −11.1 to −8.8) on placebo. Both active arms beat placebo at P < 0.0001, with estimated treatment differences of −12.0 percentage points for the full dose and −6.6 for the reduced one.[1] Ninety-one percent of randomized participants completed.
Read only that and stepping down looks close to free. The reduced arm kept two-thirds of the weight the full-dose arm kept, on a third of the drug.
The rescue column is the finding
From week 84 the protocol allowed rescue tirzepatide for anyone whose regain exceeded 50% of what they had lost. Rescue was given to 11 of 138 (8%) continuing at the maximum tolerated dose, 35 of 142 (25%) on the reduced 5 mg dose, and 60 of 90 (67%) on placebo.[1]
That is a tripling of the rescue rate produced by a dose reduction that cost only 5.3 percentage points of mean weight. The two columns disagree about how benign the step down was because they are measuring different things: the mean describes the group, and the rescue rate counts the individuals for whom the reduction did not hold. The trial’s own conclusion carries the caveat — reducing to 5 mg might provide a valuable alternative to discontinuation, although individuals’ treatment response might vary.[1] A quarter is a lot of variation. The trial was funded by the manufacturer.
The other thing the trial does not say about itself is that its de-escalation arm never de-escalated. It stepped down once and stayed there for a year. Nobody in SURMOUNT-MAINTAIN was tapered off anything.
What stopping outright produces, for scale
The withdrawal evidence is older and consistent. Randomized withdrawal after 20 weeks of semaglutide and after 36 weeks of tirzepatide both produced substantial regain against continued treatment.[2][3] The longest off-treatment follow-up comes from the STEP 1 extension, which tracked 327 participants for a year after both drug and lifestyle intervention were withdrawn at week 68. Mean loss on semaglutide had been 17.3%; participants regained 11.6 percentage points of it, finishing at a net 5.6% below where they started, with most cardiometabolic improvements reverting toward baseline.[4]
Two-thirds back in twelve months, and a third retained. Neither figure is zero, and neither is durable success.
The regain is front-loaded, which is what makes a taper plausible
A 2026 review of the discontinuation literature describes the trajectory rather than only the endpoint: regain after stopping is substantial and a large proportion of it occurs early, in the first months after cessation. The mechanistic account it assembles is a mismatch — appetite returning as pharmacological GLP-1 signaling is withdrawn, compensatory rises in orexigenic hormones including ghrelin, and altered incretin balance — arriving all at once when the drug is stopped abruptly.[5]
That is a coherent argument for smoothing the transition, and the review is careful about how far it goes. Randomized evidence suggests reduced-intensity maintenance attenuates regain compared with abrupt discontinuation. Whether a structured tapering strategy can successfully facilitate discontinuation remains unknown and requires prospective evaluation.[5] The plausible mechanism and the missing trial are both in the same paragraph.
The real-world magnitude, and what else reverts
A 2026 narrative review synthesized the randomized withdrawal trials alongside observational cohorts covering more than 289,000 patients. It reports weight regain of 60% to 90% within one year of discontinuation, with parallel reversal of cardiometabolic benefit: modeling suggests glycemic, blood pressure and lipid parameters return toward baseline within approximately 12 months and HbA1c within 12 to 18 months. It also reports that discontinuation inside the first year is associated with increased risks of coronary artery disease and heart failure against continued therapy.[6]
Its framing is the part worth carrying: discontinuation should be treated as a high-risk clinical transition rather than a treatment endpoint, and it states that validated tapering strategies do not exist.[6] That is a review of associations rather than a trial, and the people who stop early differ systematically from the people who do not.
Stretching the interval: thirty people
The other de-escalation people actually attempt is reducing frequency rather than dose. The published evidence for it is one retrospective case series of 30 adults who had plateaued on weekly semaglutide or tirzepatide and moved to reduced-frequency dosing, usually every other week, at their existing dose. Over an average of 36.3 weeks, mean weight went from 87.9 kg before treatment to 74.1 kg at plateau and to 72.4 kg on the reduced schedule (P < 0.01), with total and truncal fat falling and skeletal muscle mass stabilizing.[7]
Thirty patients, no control group, no randomization, and selected by having already done well. The authors present it as support for structured de-escalation as a promising strategy, which is the right weight to give it. What it is not is a comparison against staying on the weekly schedule, and it is a long way from the sub-therapeutic protocols discussed in the microdosing article.
The one labeled sentence that resembles a taper points backward
None of the four approved labels contains a discontinuation schedule. The closest thing is in the Wegovy injection label and it governs restarting: if 2 or more consecutive doses are missed, dosage escalation is to be reinitiated at a lower dosage, to reduce the risk of gastrointestinal adverse reactions.[8]
So the only labeled instruction about lowering a dose exists because coming back up is hard on the stomach, not because coming down is clinically staged. Whoever restarts after a gap pays the escalation cost a second time, which is also a pricing event on any plan that charges by rung — see the titration article.
The census of what nobody has measured
Four questions, all of them the ones people actually ask, and all of them unanswered by any randomized trial.
Whether a taper ending in no drug beats simply stopping. Whether any particular step schedule — how far down, how long at each step — outperforms any other. Whether a taper combined with structured behavioral or exercise support changes the trajectory, which the reviews propose and none has tested against a control. And whether any of it transfers to a compounded preparation, which is not FDA-approved and is not reviewed by the FDA for safety, efficacy or quality before it is dispensed, and which has no pharmacokinetic data of its own at any dose.
An absence stated plainly is worth more than a plan invented to fill it. Two independent 2026 reviews reached the same conclusion in their own words: validated tapering strategies do not exist, and whether structured tapering can facilitate discontinuation is unknown.[5][6]
What this changes about a purchase decision
Chiefly it removes an exit that people budget around. A course of treatment planned as six months of drug followed by a taper is planned against evidence that does not exist, and the one trial that came closest kept every participant on something for two years. Anyone costing this out should cost the maintenance phase, not the loss phase — which is why a price that holds as the dose moves matters more than an opening rate, and why sellers that hold one price are worth identifying early. What is known about treatment over years rather than months is in the long-term article.
The decision to come off a GLP-1 belongs to the person taking it and the clinician who prescribed it, and there is a legitimate version of it: cost, side effects, pregnancy planning, or a judgment that the trade is no longer worth it. What the evidence does not supply is a schedule that makes it land softly. Anyone being sold one is being sold something nobody has tested.